article · European Journal of Case Reports in Internal Medicine
Background: Anti-interleukin-6 receptors (anti-IL-6R) have been a promising new therapeutic alternative in the treatment of Takayasu arteritis. Case description: We report the case of a 34-year-old patient with Takayasu arteritis diagnosed in 2017. While she was on corticosteroid and methotrexate, the patient presented twice with clinical and radiological signs of activity, requiring an increase of corticosteroid dose and an increase in the methotrexate dose to 20 mg/week. Anti-IL-6R infusions were indicated. At the end of the fifth infusion, the patient was totally asymptomatic: she no longer experienced episodes of syncope or amnesia. Conclusion: Our case perfectly illustrates the effectiveness of anti-IL-6R in the treatment of Takayasu arteritis, especially in its refractory form. LEARNING POINTS: Takayasu arteritis may have a significant functional impact that affects quality of life.Tocilizumab is a very interesting therapeutic alternative in the refractory form of Takayasu arteritis.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.12890/2024_004868
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
